CPT1A Knockout HAP1 Cell Line

The choice depends on whether you are studying CPT1A (carnitine palmitoyltransferase 1A)'s role as the rate-limiting enzyme of long-chain fatty acid β-oxidation or modeling CPT1A deficiency and emerging cancer metabolism applications. The Knockout line is the standard tool for asking whether CPT1A is required for these processes — CPT1A catalyzes the conjugation of long-chain acyl-CoA with carnitine on the outer mitochondrial membrane, generating long-chain acylcarnitine that can be translocated into mitochondria via CACT (SLC25A20) for β-oxidation; CPT1A is the liver/most-tissue isoform (CPT1B is muscle-specific, CPT1C is brain). CPT1A is inhibited by malonyl-CoA (the first intermediate of fatty acid synthesis), providing reciprocal regulation of lipid oxidation and synthesis. Overexpression is useful for studying CPT1A gain-of-function effects. For fatty acid metabolism research, the EDITGENE CPT1A Knockout in HAP1 enables study of long-chain FAO biology. CPT1A biallelic loss-of-function causes CPT1A deficiency (autosomal recessive disorder of FAO with hepatic encephalopathy, hypoglycemia); a CPT1A P479L variant is common in Arctic Inuit populations. Rescue with wild-type, catalytically-dead, or malonyl-CoA-insensitive (M593S, M593G — malonyl-CoA-resistant CPT1A) enables structure-function studies. The knockout is a critical specificity control for etomoxir (CPT1A inhibitor used in metabolic research and as a tool compound), perhexiline (FDA-approved anti-anginal), and emerging CPT1A-targeted therapeutics in cancer (CPT1A is upregulated in many cancers as a fatty acid oxidation dependency).

Primary applications: • Long-chain FAO: ¹⁴C-palmitate oxidation analysis and acylcarnitine profiling to characterize CPT1A-dependent FAO. • Cancer metabolic dependency: cell growth and survival under glucose-limited conditions given the CPT1A FAO dependency in many cancers. • Etomoxir specificity: critical genetic control for etomoxir (CPT1A inhibitor research tool) — etomoxir should have no effect on FAO in CPT1A-null cells. • Arctic Inuit variant studies: rescue with P479L CPT1A variant for genotype-function studies of the common Arctic Inuit variant. • Malonyl-CoA regulation: rescue with M593S/M593G malonyl-CoA-resistant CPT1A for studying lipid synthesis/oxidation coordination. EDITGENE recommends this model for researchers investigating fatty acid oxidation, CPT1A deficiency, and emerging CPT1A-targeted cancer metabolic therapeutics.

Yes. CPT1A rescue experiments require attention to mitochondrial outer membrane targeting: • Construct design: use a codon-modified CPT1A sequence with a small C-terminal tag (FLAG, HA). CPT1A has N-terminal mitochondrial outer membrane targeting (two transmembrane spans), central catalytic domain (acyltransferase activity), and C-terminal regions including malonyl-CoA binding site — preserve all elements. • Mitochondrial outer membrane localization validation: confirm MOM localization before functional assays. • Catalytically-dead rescue: His473 or other catalytic residue mutations abolish acyltransferase activity. • Malonyl-CoA-insensitive rescue: M593S or M593G mutations generate malonyl-CoA-resistant CPT1A, enabling separation of FAO regulation by malonyl-CoA from catalytic activity. • Patient mutation rescue: P479L (Arctic Inuit) and other patient-derived CPT1A mutations enable disease genotype-function studies. • Functional readout: rescue should restore long-chain FAO measured by ¹⁴C-palmitate oxidation. HAP1-specific considerations: • Diploidization: HAP1 cells gradually diploidize during extended culture — confirm ploidy by flow cytometry at the time of phenotypic assay. • Integration site sensitivity: position effects on transgene expression are more pronounced in near-haploid backgrounds; generating multiple independent rescue clones is strongly recommended. • Transduction efficiency: HAP1 transduces with lentivirus at moderate efficiency — increase MOI compared to standard immortalized lines.